Gilead's Hep C Drug Granted EU Approval

Jan 20, 2014

The European Commission has approved Gilead Sciences' potential blockbuster drug Sovaldi (sofosbuvir) as a combination therapy for treating adults suffering from chronic Hepatitis C virus.

Once granted by the European Commission, a "Marketing Authorization" is valid in all European Union member states, as well as in the European Economic Area countries Iceland, Liechtenstein and Norway.

The US FDA granted approval to Sovaldi in early December, and Gilead is also seeking approval of the drug in Australia, New Zealand, Switzerland and Turkey.